Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16703428 | 0.89 | CTNNB1 (0.43) | KMT2AMEN1RENTSHRALDH1A1 | |
| SCHEMBL10187777 | 0.87 | ALDH1A1 (0.40) | KMT2AMEN1RENTSHRALDH1A1 | |
| SCHEMBL6168541 | 0.73 | NOTUM (0.45) | TSHRALDH1A1MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL4814573 | 0.71 | TYK2 (0.50) | KMT2AMEN1TSHRALDH1A1HSD17B10 | |
| SCHEMBL30367555 | 0.71 | TYK2 (0.50) | KMT2AMEN1TSHRALDH1A1HSD17B10 | |
| SCHEMBL15999061 | 0.70 | ROCK1 (0.48) | TSHRKDM4EALKBH2EGLN1 | |
| SCHEMBL25778550 | 0.68 | KDM4E (0.66) | TSHRALDH1A1HSD17B10CYP3A4CYP2C9 | |
| SCHEMBL25778552 | 0.68 | L3MBTL1 (0.51) | TSHRALDH1A1HSD17B10CYP3A4MAPK1 | |
| SCHEMBL28773938 | 0.68 | KDM4E (0.43) | KMT2ATSHRALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL31525628 | 0.68 | NAPRT (0.39) | TSHRKDM4EALKBH2EGLN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614234-B2 | Compounds as tyrosine kinase modulators | ALLERGAN, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| EP-2473501-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | Allergan, Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20110053905-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053905-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ABL1, ERBB2, LCK | KMT2A 2169/4885MEN1 3540/4885REN 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.